dldopa

DL-Dopa is a phenylalanine beta-hydroxylated derivative.

L-Dopa-2,5,6-d3 is a deuterated compound of L-Dopa. L-Dopa has a CAS number of 59-92-7. Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain,  levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS.

L-DOPA (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and be converted into dopamine in the brain. L-DOPA exhibits anti-hyperalgesic effects and holds potential in Parkinson’s disease research, and it can also be used to induce Parkinson’s disease models.

Levodopa sodium (L-DOPA) is the metabolic precursor of the neurotransmitter dopamine. It is orally active, capable of crossing the blood-brain barrier, and is rapidly taken up by dopaminergic neurons in the brain where it is converted into dopamine. It exhibits anti-hyperalgesic effects and is commonly used to induce animal models of Parkinson's disease.